Axovant Sciences: Betting On An Improved Risk Profile
I took immediate notice when Axovant Sciences (AXON) went public back in late 2015. The promise of a treatment for Alzheimer’s was a huge opportunity, and I immediately had thoughts of my grandfather who struggled with the disease for years before he passed away with a heart attack. Yet, AXON had no revenues and no … Read more